These results are encouraging and strengthen the hypothesis that statins may be useful for lung cancer chemoprevention. However, as pointed out by the authors,11 the study has weaknesses innate to its design. Firstly, it is a retrospective analysis of mainly male veterans, and thus only partially representative of the diverse population of the United States. In particular, the impact of statins on lung cancer risk in women cannot sufficiently be addressed. Secondly, the interaction between tobacco and statin use can only be marginally investigated in the data set because of uncertainties in data accuracy. Other exposures to chemicals, radiation, and potentially carcinogenic substances were not explored in depth. Statins were obviously used in this population for specific clinical indications, thus limiting the observation to patients with specific medical conditions. Finally, aside from the lung cancer risk reduction, patients with a < 6-month use of statins had an increased risk of lung cancer, which raises the question of a potential tumor promoting effect of statins.